# Investigating the Multi-Targeted Pharmacological profile of an Exopolysaccharide from Bacillus rugosus SYG20 via In Vitro Evaluation of its Antioxidant, Anti-inflammatory, Anti-diabetic, Wound Healing, and Antimicrobial Properties

**Keywords**
H.pylori, Antioxidant, Anti-inflammatory, Antimicrobial, Antidiabetic, Antibiofilm, Antiobesity

**Abstract**

Introduction
Exopolysaccharides (EPSs) derived from marine microorganisms are a newly recognized reservoir of bioactive therapeutic compounds

Material and methods
We isolated a high EPS-yielding bacterial strain from the Red Sea, identified as Bacillus rugosus SYG20. Its purified EPS (EPSR9) contains 45.33% uronic acid, 9.98% sulfate groups, and 5.40% N-acetyl glucosamine. The HPLC chromatogram revealed four monosaccharides - glucose, xylose, galacturonic acid, and arabinose, in a distinct molar ratio of 2:3:1:1. EPSR9 showed a wide array of bioactivities.

Results
It displayed antioxidant activity with an IC50 of 25.6 µg/ml in the DPPH assay and a total antioxidant capacity (TAC) of 417.77µg/ml equivalent AAE and 62.67 µg/ml equivalent AAE in Ferric reducing antioxidant power (FRAP) assays. It exhibited substantial anti-inflammatory properties. The anticoagulant effect of the EPS was demonstrated by a dose-dependent increase in prothrombin time. The scratch assay resulted in a 72.66% increase in wound closure, promoting in vitro wound healing after 48 h. Anti-obesity activity was evidenced by 83.8% lipase inhibition at 1000 µg/ml with IC50 of 107.73µg/ml. EPSR9 demonstrated inhibitory effects on α-amylase with an IC50 value of 14.37µg/ml and α-glucosidase with an IC50 value of 26.73 µg/ml, highlighting its potential as an anti-diabetic agent. Then, EPS showed bactericidal properties with MBC/MIC≤2 against both G+ve and G-ve bacteria, Staphylococcus aureus , Enterococcus faecalis (MIC=3.9µg/ml), Salmonella typhi, and Helicobacter pylori.

Conclusions
The marine EPSR9 exhibited considerable potential for pharmaceutical applications as a multi-bioactive microbial metabolite. Its in vivo potency and mechanisms of action warrant further investigation.

# Investigating the Multi-Targeted Pharmacological profile of an Exopolysaccharide from *Bacillus rugosus* SYG20 via In Vitro Evaluation of its Antioxidant, Anti-inflammatory, Antidiabetic, Wound Healing, and Antimicrobial Properties

**Abstract**

**Introduction**: Exopolysaccharides (EPSs) derived from marine microorganisms are a newly recognized reservoir of bioactive therapeutic compounds.

**Material and Method**: We isolated a high EPS-yielding bacterial strain from the Red Sea, identified as *Bacillus rugosus* SYG20. Its purified EPS (EPSR9) contains 45.33% uronic acid, 9.98% sulfate groups, and 5.40% N-acetyl glucosamine. The HPLC chromatogram revealed four monosaccharides - glucose, xylose, galacturonic acid, and arabinose, in a distinct molar ratio of 2:3:1:1. EPSR9 showed a wide array of bioactivities.

**Results**: It displayed antioxidant activity with an $IC_{50}$ of 25.6 µg/ml in the DPPH assay and a total antioxidant capacity (TAC) of 417.77µg/ml equivalent AAE and 62.67 µg/ml equivalent AAE in Ferric reducing antioxidant power (FRAP) assays. It exhibited substantial anti-inflammatory properties by inhibiting 81.8-99% of hypotonic solution-induced hemolysis of HRBCs at 100-1000 µg/ml. The anticoagulant effect of the EPS was demonstrated by a dose-dependent increase in prothrombin time from 18.7 to 49.3 sec and partial thromboplastin time from 33.5 to 60.3 sec at 25 -75 µg/ml. The scratch assay resulted in a 72.66% increase in wound closure, promoting in vitro wound healing after 48 h. Anti-obesity activity was evidenced by 83.8% lipase inhibition at 1000 µg/ml with $IC_{50}$ of 107.73µg/ml. EPSR9 demonstrated inhibitory effects on α-amylase with an $IC_{50}$ value of 14.37µg/ml and α-glucosidase with an $IC_{50}$ value of 26.73 µg/ml, highlighting its potential as an antidiabetic agent. Then, EPS showed bactericidal properties with MBC/MIC≤2 against both G+ve and G-ve bacteria, *Staphylococcus aureus* (MIC=62.5µg/ml), *Enterococcus faecalis* (MIC=3.9µg/ml), *Salmonella typhi* (MIC=31.25µg/ml), and *Helicobacter pylori* (MIC=31.25µg/ml). Additionally, it showed concentration-dependent anti-biofilm activity, achieving up to 88% for *Salmonella typhi,* 86.08 % for *Klebsiella pneumoniae*, and remarkable antibiofilm activity at 95.60 % for *H.pylori* at 75% MBC.

**Conclusion**: The marine EPSR9 exhibited considerable potential for pharmaceutical applications as a multi-bioactive microbial metabolite. Its in vivo potency and mechanisms of action warrant further investigation.

**Keywords**: Antioxidant, Anti-inflammatory, Anti-obesity, Antidiabetic, Antimicrobial, *H.pylori*, Antibiofilm

## Introduction

Marine ecosystems occupy a significant portion, around 71%, of the Earth's surface. These diverse habitats are sustained by the vital functions performed by various bacterial populations [1]. Exopolysaccharide (EPS), a principal organic compound produced by ocean microorganisms, accounts for approximately half of the primary generation of organic matter. These polymers play a crucial role in maintaining marine environments by facilitating sedimentation, particle formation, and the cycling of dissolved metals and organic carbon [2]. Exopolysaccharides are essential for the growth and survival of organisms in harsh marine environments. These polymers facilitate crucial functions such as nutrient uptake, aggregation, adherence to surfaces, and the production of biofilms, which are vital for the survival and thriving of marine organisms [3].

Microbial polysaccharides are hydrophilic biopolymers that might be intracellular, structural, or exopolysaccharides exhibiting various intriguing properties, such as biocompatibility, biodegradability, and nontoxicity [4]. When comparing EPS with the first two groups, EPS exhibits a broader range of applications and employs more extensive methodologies for extraction and processing [5–7]. Numerous fungi, algae, and Gram-positive and Gram-negative bacteria can produce EPS [8]. The formidable, harsh marine ecosystem has the potential to elicit the synthesis of EPSs by marine microorganisms [3]. They provide microorganisms the potential to enhance their tolerance towards biotic and abiotic stressors [9]. Most microbial EPSs exhibit heterogeneity in their composition, consisting of diverse monosaccharides such as glucose, galactose, glucuronic acid, and others, arranged in a specific and characteristic ratio [10].

Microbial EPSs typically have high molecular weights, ranging from 10 to 6,000 kDa [11]. The anionic nature of most reported EPS is primarily attributed to the presence of pyruvate and uronic acid moieties linked to ketals and the inclusion of inorganic residues such as sulfate or phosphate groups [12]. Due to the growing demand for natural polymers in industries like food and pharmaceuticals, there has been a recent surge in interest in microbially produced polysaccharides [12].

The recovered EPS from different bacterial strains exhibited substantial physicochemical and structural variations [13]. Marine EPSs show a considerably higher degree of complexity and diversity in bioactivities compared to terrestrial origins [14]. These bacterial metabolites may have potential uses as anti-inflammatory, antioxidant, antimicrobial, and anticytotoxic agents, in addition to various other pharmacological applications. The most well-known producers of EPSs are bacteria belonging to the genera *Lactobacillus*, *Bifidobacterium*, *Leuconostoc*, *Pediococcus*, *Streptococcus*, *Enterococcus*, and *Weissella* Sp [15,16]. Furthermore, EPS generated by specific *Lactobacillus* species, such as

*Lactobacillus acidophilus*, *Lactobacillus gasseri*, *Lactobacillus plantarum*, and *Lactobacillus rhamnosus*, isolated from diverse sources, has been shown to exhibit antitumor as well as antioxidant properties [17]. Interestingly, EPSs produced by *Lactobacillus plantarum*, *Lactobacillus acidophilus*, and *Lactobacillus helveticus* are the most commonly reported EPS with good anticancer properties among EPS-producing species [18]. Even within the same bacterial species, the antiproliferative activity of the EPS can vary from strain to strain [19].

Building upon this foundation, existing research has revealed that microbial EPSs possess a diverse range of therapeutic potential, including antibacterial [20,21], antioxidant [22,23], anti-inflammatory [24,25], anticancer [23,24], and gel-forming attributes [26]. Furthermore, numerous studies have documented the ability of certain EPSs to modulate wound cellular metabolism, facilitating tissue repair and regeneration and accelerating the healing process [27,28]. In addition, recent investigations have successfully isolated sulfated polysaccharides exhibiting notable anticoagulant functionalities from various marine species [29–31]. These investigations aimed to identify an alternative anticoagulant to heparin, a glycosaminoglycans (GAGs) family member characterized by its sulfated polysaccharide structure [32]. Several reasons make heparin alternatives preferable. Some religious groups avoid heparin because it comes from pig intestines and bovine lungs. Additionally, heparin is linked to fatal disorders. Liu et al. found that critical COVID-19 patients treated with heparin have a high mortality risk from thrombocytopenia [33]. These drawbacks have spurred researchers to find safer, more effective alternatives [30,34,35].

Given the remarkable biomedical applications of microbial EPSs and the perpetual efforts to discover and explore new bioactive bacterial EPSs, the current investigation aimed to isolate novel bioactive compounds from marine bacteria collected from the Red Sea, with the potential for development into pharmaceutical and therapeutic drugs. The specific objectives of this study were as follows: Primary screening and isolation of the marine bacterium with the highest EPS production, followed by 16S rRNA molecular identification; Chemical characterization and analysis of the generated EPS using Fourier-transform infrared (FT-IR) spectroscopy, high-performance liquid chromatography (HPLC); Assessment of the EPS's antioxidant properties through 2,2-diphenyl-1-picrylhydrazyl (DPPH), total antioxidant capacity (TAC), and ferric reducing antioxidant power (FRAP) assays, as well as its anti-inflammatory potential using human red blood cell (HRBC) hemolytic and membrane stabilization assays; Evaluation of the EPS's anticoagulant activity through classical prothrombin time (PT) and partial thromboplastin time (PTT) assays, and investigation of its wound healing potential; In vitro assessment of the EPS's lipase inhibitory activity, as well as its antidiabetic effects through α-amylase and α-glucosidase inhibition studies; and examination of the EPS's antimicrobial and

antibiofilm properties against a panel of Gram-positive (G+ve) and Gram-negative (G-ve) pathogenic bacteria, including *Helicobacter pylori*.

## Material and Methods

### 1- Sampling of Red Sea Bacteria and Selection of Isolates for Molecular Analysis

Bacterial specimens were obtained and separated from sand samples from the Red Sea using the serial dilution technique [36]. The bacterial strains were carefully chosen considering their culture growth characteristics and their maximum production rate of EPS.

The bacterial genetic classification was conducted by employing a 16S rRNA sequence, which was subsequently subjected to additional phylogenetic analysis [37]. Using the BLAST tool, the acquired DNA sequence was compared with the GenBank database at the NCBI. Subsequently, a sequence alignment was conducted to assess the degree of similarity between the isolate's sequence and those present in the database.

### 2- Production, Extraction, and Physicochemical Characterization of Bacterial EPS

For producing EPS, the promising strain, R9, was selected. The final step involved the addition of the fermentation medium broth, as described by Liu et al. [38]. A total of 4 liters of ethanol was introduced into the supernatant for fractional precipitation. Examining the UV absorption spectra in the 200 to 800 nm wavelength range to determine the presence of proteins and nucleic acids [39]. FTIR spectra were analyzed utilizing the FTIR-UNIT Bruker Vector 22 Spectrophotometer [40]. The identification of uronic acid in the EPS was achieved by employing the colorimetric method described by Filisetti-Cozzi and Carpita [41]. The sulfate content was quantified using Garrido's method [42]. The methodology described by Randall et al. was employed to investigate the monosaccharide content of the specimen using an Aminex carbohydrate HP-87C column (300 x 7.8 mm) at a flow rate of 0.5 ml/min. Water was employed as the eluent, and the detector was refractive index (RI). Acid hydrolysis was performed by hydrolyzing a known quantity of EPSR9 (15 mg) with HCOOH (88%) in a sealed vessel at 100$^{o}$C for 5 hours. Afterward, the hydrolysate was quantitatively transferred to a crucible and HCOOH evaporated to dryness under vacuum at 40$^{o}$C. The hydrolysate was then washed with $dH_2O$ and concentrated under vacuum after repeatedly evaporating to eliminate the formic acid. The sample was frozen in a sealed vial for later analysis. Next, HPLC was used to separate and quantify the EPSR9 hydrolysate by analyzing the mono sugars on an Agilent Pack series 1200 instrument equipped with an Aminex carbohydrate HP-87C column (300 mm × 7.8 mm). Peaks were identified by comparing

retention times to known reference standards. Concentrations of sugars were calculated from retention times and peak areas using Agilent Packard data analysis [43].

## 4- Antioxidant Evaluation of the EPS

### 4.1. DPPH Test

The antioxidative capacity of the EPS was assessed at various concentrations (1.95 -1000 µg/ml) using the methodology described by Brand-Williams [44]. The spectrophotometer (UV-VIS Milton Roy) was employed to measure the absorbance at a wavelength of 517 nm. The experimental procedure involved applying ascorbic acid as the reference standard, and the testing method was carried out in triplicate. The $IC_{50}$ value of the EPS was determined by constructing a logarithmic dose-inhibition curve.

### 4.2. TAC examination

The quantitative examination of the EPS was performed using spectrophotometric analysis adopting the phosphomolybdenum approach described by Prieto et al. [45]. The quantification of absorbance at a wavelength of 630 nm using a microtiter plate reader (Biotek ELX800; Biotek, Winooski, VT, USA). Calculating the values was performed by the ascorbic acid equivalent (AAE) unit, expressed in µg/mg of the tested EPS, as outlined by Lahmass et al. [46].

### 4.3. FRAP assay

To investigate the impact of solvent polarity on the overall declining capacity of the EPS, the potassium ferricyanide trichloroacetic acid method outlined by Benzie and Strain was employed [47]. The measurements were conducted at a wavelength of 630 nm using a microtiter plate reader (Biotek ELX800; Biotek, Winooski, VT, USA). In the experimental setting, DMSO was the negative control, while ascorbic acid at 1 mg/ml was used as the positive control. The outcomes' quantification was expressed in ascorbic acid equivalent (AAE) µg/mg of the EPS.

## 5. Anti-inflammatory human red blood cells (RBCs) and membrane stabilization (HRBCs-MSM) assay

A blood sample was taken from the author according to the research ethics committee (Ref.No.ERUFP-PM-23-001) from the Egyptian Russian University. The study of in vitro anti-inflammatory activity was conducted using the HRBCs-MSM method, following the protocol described by Anosike et al. [48].

6. **Anticoagulant evaluation of the EPS by PT and PTT tests**

Assays, PT, and APTT were tested: After combining citrated normal human plasma with a sample concentration solution, the mixture was incubated for three minutes at 37°C. Next, for PT testing, 0.20 ml of PT test reagent was added to the mix and pre-incubated for three minutes at 37 °C, then the clotting time was noted. Similarly, 0.10 ml of PTT assay reagent was preincubated and added to the mixture under the same conditions afterward; 0.025 mol/l was preincubated for 3 minutes at 37, and the clotting time was recorded [49].

**7. Wound healing assessment of EPS**

Human normal skin fibroblasts, the HFB4 cell line, were obtained from the Holding Company for Biological Products and Vaccines (VACSERA) in Cairo, Egypt. The cells were seeded into six multi-well plates and allowed to grow until reaching confluency. At the start of the experiment, it was essential that all cell cultures had attained a confluent monolayer. A straight scratch was made using a yellow pipette tip to simulate a wound. To minimize the scratch breadth, we frequently produce the scratch with the pipette tip at an angle of about 30 degrees. This enables imaging with the 10x objective of both wound edges [50].

**8. Anti-lipase in vitro inhibition**

Lipase stock solutions (1 mg/ml) were prepared in a 0.1 mM $K_3PO_4$ buffer (pH 6.0) and stored at -20 °C. P-nitrophenyl butyrate (PNPB) was used to assess lipase inhibition activity. EPS at different concentrations (1.95- 1000 µg/ml) and Orlistat at comparable doses were pre-incubated with lipase for 1 hour at 30°C in a potassium phosphate buffer to ascertain their lipase inhibitory action. Next, 0.1µl of PNPB was added as a substrate to initiate the reaction at a final volume of 100µl. The reaction's release of p-nitrophenol was measured at 405 nm using a Biosystem 310-plus UV-visible spectrophotometer following a 5-minute incubation period at 30°C [51]. In addition, the negative control's activity was evaluated both with and without the inhibitor.

**9. EPS antidiabetic assessment**

**9.1. Anti α-amylase testing**

The α-amylase inhibition analysis was conducted by applying the 3,5-dinitrosalicylic acid (DNSA) method described by Wickramaratne et al. [52]. The concentrations of EPS ranged from 1.95 to 1000 µg/ml and were compared to the acarbose standard control, which also ranged from 1.95 to 1000 µg/ml. The absorbance measurements were taken at a wavelength of 540 nm using a UV-visible

Biosystem 310 spectrophotometer. The $IC_{50}$ values were derived from the graph by graphing the α-amylase inhibition % versus the concentration of EPS.

### 9.2. Anti- α-glucosidases examination

The methodology proposed by Pistia-Brueggeman and Hollingsworth (2001) was employed to evaluate the α-glucosidase inhibitory activity. The experimental EPS was tested at 1.95 to 1000 µg/ml concentrations. The results were then compared to those of the acarbose control, which also encompassed concentrations ranging from 1.95 to 1000 µg/ml. The absorbance measurements were conducted at a wavelength of 405 nm using a Biosystem 310 plus spectrophotometer. The $IC_{50}$ values were calculated using a regression equation from graphing the doses tested against the enzyme inhibition [53].

### 10. Antimicrobial evaluation against G+ve and G-ve pathogenic bacteria

The antimicrobial effects of the EPS were evaluated using the agar well diffusion method against a range of bacterial strains from the ATCC collection. G+ve *Bacillus Subtilis* (ATCC 6633) *Staph. aureus* (ATCC 6538) and *Enterococcus faecalis* (ATCC 29212). G-ve bacteria were *Escherichia coli* (ATCC 8739), *K. pneumoniae* (ATCC13883), and *Salmonella typhi* (ATCC 6539). The dried agar is smeared in three directions. Following a 15-minute drying period, an aseptic technique is employed to create a hole in the agar using either a sterile cork borer with a diameter of 6 to 8 mm. gentamicin was utilized as the control drug, and both gentamicin and EPSF8 were solubilized in DMSO at a concentration of 10mg/ml. Subsequently, 100 units of EPSF8 were introduced into the well. The plates were incubated for 16-48 hours immediately after disposal, and the widths of the inhibition zones surrounding the wells were measured to the nearest whole millimeter when there was a noticeable reduction in growth [54]. The investigation of minimum inhibitory concentrations (MICs) and minimum bactericidal concentrations (MBCs) was subsequently conducted under the guidelines set forth by the Clinical and Laboratory Standards Institute (CLSI) [55].

The anti-*H. pylori* activity was determined by the well agar diffusion method using Mueller Hinton agar plates containing 10% sheep blood. Wells were punched into the agar and filled with 100 µl of the antimicrobial agent solutions at desired concentrations. DMSO was used as the negative control. Positive controls were amoxicillin at 0.05 mg/ml, clarithromycin at 0.05 mg/ml, and metronidazole at 0.8 mg/ml. After 72 hours of incubation at 37°C under microaerophilic conditions with humidity, the diameter of the inhibition zone around each antimicrobial agent well was measured and compared to the positive and negative controls.

### 11. Antibiofilm evaluation of the EPS

The impact of EPS on biofilm development was evaluated using 96-well polystyrene flat-bottom plates. To summarize, 300 $\mu$l of trypticase soy yeast broth (TSY) containing a final concentration of $10^6$ CFU/mL was subjected to cultivation to 75%, 50%, and 25% of MBC of the previously tested organisms excluding *E.coli*. After two days of incubation at 37°C, the biofilm on the plates was dyed with 0.1% crystal violet aqueous solution for 15 minutes. After the incubation period, sterile $dH_2O$ was used to remove any residual stain from the plate. 250 $\mu$l of 95% $C_2H_5OH$ was added to each well to dissolve the dye adhered to the cells. After 15 minutes, absorbance was measured at 570 nm using a microplate reader [56].

### Statistical analysis

Triplicates were used for all tests. The results are shown as mean±SD, and data were evaluated using one-way ANOVA and Tukey post hoc test. T-test was applied for comparisons by SPSS program (V25), n=3, $p \leq 0.05$.

## Results

### 1- Screening, identification, and Phylogenetic Identification of High EPS Producing Isolate

A comprehensive collection of 12 bacterial isolates derived from marine sediment samples from the Red Sea was obtained and submitted to a rigorous screening process to determine their ability to synthesize EPS. The screening procedure encompassed assessing cultural traits and morphological parameters and quantifying EPS production yield. The strain R9 of the marine bacterium exhibited the largest EPS yield (5.21g/l). This EPS production predominantly comprised a major fraction, constituting 86.01% (three-volume ethanol). Microbiological analysis was conducted on the chosen strain. The morphological and culture examination indicates a Gram +ve short rod that forms large, opaque white colonies with a rough and irregular surface morphology (Table S1). The biochemical and physiological tests revealed a catalase-positive, starch-hydrolyzing bacterium that can reduce nitrate, ferment certain carbohydrates like glucose and sucrose, and doesn't with maltose and lactose (Table S2). Molecular 16srRNA sequencing followed, and the phylogenetic tree compared sequences that showed considerable similarity to the bacterium's rRNA sequences. The acquired rRNA gene sequences matched *Bacillus rugosus* SYG20 (Figure 1), proving the tree was assembled successfully. Accession number (OR673614) confirmed *Bacillus rugosus* SYG20 identification. The DNA sequence was analyzed using BLAST and submitted to NCBI GenBank.


**Figure 1.** Phylogenetic tree analysis of *Bacillus rugosus* SYG20 based on 16S rRNA gene sequencing.

## 2- Structural and compositional analysis using UV, FT-IR, HPLC, uronic acid, and sulfate quantification.

*Bacillus rugosus* SYG20 strain was selected as the preferred candidate for producing exopolysaccharide (EPSR9), achieving a 5.21g/L yield. The unrefined residue underwent a purification process that included fractionation and precipitation. The EPSR9 sample was filtered through a membrane with a pore size of 100 microns after being treated with deionized water for three days. The EPSR9 that had undergone dialysis was treated with a progressive treatment with cold $C_2H_5OH$, resulting in fractional precipitation. Three ethanol precipitation procedures created the EPSR9 core fraction (86.01%) from crude EPS. The resulting fraction was then exposed to UV absorption spectra ranging from 200 to 800 nm (Figure S1). EPSR9 had uronic acid (45.33%), sulfate (9.98 %), and N-acetyl glucose amine (5.40 %). As demonstrated by the FT-IR, the broad characteristic peak at 3275.03 $cm^{-1}$ was assigned to $OH^{-1}$ stretching vibration. The band at 2928.15 $cm^{-1}$ corresponded to the sugar ring's C-H stretching vibration. Also, absorption at 1632.68 $cm^{-1}$ referred to $COO^-$ vibration and 1338.10 $cm^{-1}$. The band at 1077.06 $cm^{-1}$ indicated the $SO^{=3,}$ and present was characteristic absorption at 860.28 $cm^{-1}$ arising from β-configuration of the sugar units (Figure 2).




**Figure 2.** EPSR9's FTIR spectra show the primary functional groupings.

The HPLC chromatogram of EPSR9 revealed the monosaccharide fractions (Glucose: xylose: galacturonic acid: arabinose) with molar ratios of 2: 3: 1: 1, respectively (Figure 3).




**Figure 3.** HPLC chromatogram of the EPSR9 from *Bacillus rugosus* SYG20

### 3- Antioxidant Evaluation of EPSR9 by DPPH, TAC and FRAP

EPSR9 exhibited a noticeable dose-dependent and progressive increase in DPPH scavenging from 20.0% to 92.5% as the concentration increased from 1.95 to 1000 µg/ml across triplicate measurements. The $IC_{50}$ value for EPSR9 was 25.6 ± 0.001 µg/ml (Figure 4). The standard antioxidant ascorbic acid showed higher potency, with an $IC_{50}$ of 2.52 ± 0.001 µg/ml (Figure S2). Though EPSR9 displayed lower antioxidant activity than ascorbic acid, it still

showed appreciable, dose-dependent radical scavenging capabilities. EPSR9 achieved 92.5% DPPH scavenging at the highest tested concentration compared to 99.3% for ascorbic acid.




**Figure 4.** EPSR9 (1.95 to 1000 µg/ml) DPPH radical scavenging % vs ascorbic acid. Results represented as mean ± SE. One-way ANOVA (n = 3, P ≤ 0.05)

Complementary assays comprehensively evaluated EPSR9's antioxidant potential through different mechanisms and reaction environments. The TAC evaluation using the phosphomolybdenum method was conducted for EPSR9, resulting in a 417.77 AAE equivalent µg/ml (Table 1). This was compared to the TAC ascorbic control (Figure S2). EPSR9 was determined to possess a FRAP AAE equivalent concentration of 62.67 µg/ml, as indicated in (Table 2). This value was compared to the FRAP of the ascorbic acid standard, as reported in (Figure S3).

**Table 1.** Antioxidant capacity and reducing the power of EPSR9 measured in ascorbic acid equivalents (AAE).

| EPSR9 (AAE) µg/mg | TAC (equivalent (AAE) µg/mg) Mean± SE | FRAP (equivalent (AAE) µg/mg) Mean± SE |
|---|---|---|
| | 417.77±0.078 | 62.67± 0.078 |

**4-Anti-inflammatory assessment of EPSR9 by HRBC hemolytic and membrane stabilization assay**

EPSR9 demonstrated significant in vitro anti-inflammatory effects in the HRBC hemolytic and membrane stabilization assay, evidenced by dose-dependent inhibition of hemolysis. EPSR9 at 100-1000 µg/ml concentrations progressively inhibited hypotonic solution-induced erythrocyte hemolysis from 81.8% to 99.0% (Table 2). The standard anti-inflammatory drug indomethacin showed a dose-responsive

reduction in HRBC lysis from 93.3% to 99.5% inhibition at 100-1000 µg/ml. At its highest tested concentration (1000 µg/ml), EPSR9 demonstrated comparable anti-inflammatory effects of 99% compared to 99.5% at the same tested concentration for indomethacin, preventing almost complete HRBC hemolysis.

**Table 2.** Dose-responsive inhibition of HRBC hemolysis by EPSR9 and indomethacin

| | | Mean Absorbance ± SE | | |
|---|---|---|---|---|
| **Sample** | **Conc.(µg/ml)** | **Hypotonic Solution** | **Isotonic solution** | **Hemolysis Inhibition%** |
| **Control** | | 1.354±0.006 | 0 | 0 |
| **EPSR9** | 1000 | 0.046±0.001 | 0.033±0.000 | 99.0 |
| | 800 | 0.080±0.001 | 0.025±0.000 | 95.9 |
| | 600 | 0.104±0.002 | 0.02±0.000 | 93.7 |
| | 400 | 0.175±0.011 | 0.016±0.000 | 88.1 |
| | 200 | 0.209±0.002 | 0.012±0.000 | 85.3 |
| | 100 | 0.254±0.002 | 0.009±0.000 | 81.8 |
| | **Conc. (µg/ml)** | **Hypotonic Solution** | **Isotonic solution** | **Hemolysis Inhibition %** |
| **Control** | | 1.354±0.006 | 0 | 0 |
| **Indomethacin** | 1000 | 0.015±0.000 | 0.008±0.000 | 99.5 |
| | 800 | 0.020±0.000 | 0.006±0.000 | 98.9 |
| | 600 | 0.034±0.001 | 0.006±0.000 | 97.9 |
| | 400 | 0.057±0.001 | 0.004±0.000 | 96.0 |
| | 200 | 0.073±0.000 | 0.003±0.000 | 94.8 |
| | 100 | 0.092±0.001 | 0.001±0.000 | 93.3 |

**4- Dose-Dependent Anticoagulation by EPSR9 in Coagulation Screening Tests**

The exopolysaccharide EPSR9 exhibited dose-dependent anticoagulant activity in vitro as measured by PT and PTT assays. At 25-75 µg/ml concentrations, EPSR9 progressively extended PT from 18.7 to 49.3 seconds compared to 13 seconds for the standard control. Similarly, EPSR9 dose-dependently increased PTT from 33.5 to 60.3 seconds versus 28 seconds for the typical control sample. The standard anticoagulant heparin showed greater potency, increasing PT to 22.5-99.8 seconds and PTT to 66.1-145.7 seconds at the same concentrations. While EPSR9 demonstrated lower anticoagulant effects than heparin, it still displayed significant dose-responsive antithrombotic activities in both assays (Table 3).

**Table 3.** Effect of EPSR9 on PT and PTT in vitro

| | EPSR9 µg/ml | | | |
|---|---|---|---|---|
| **PT (Sec)** | **0** | **25 µg** | **50µg** | **75µg** |
| EPSR9 | 13.0 | 18.7 | 34.9 | 49.3 |
| Heaprin (control) | 13.0 | 22.5 | 49.8 | 99.8 |
| **PTT(Sec)** | **0µg** | **25µg** | **50µg** | **75µg** |
| EPSR9 | 28 | 33.5 | 39.2 | 60.3 |
| Heparin (control) | 28 | 66.1 | 93.8 | 145.7 |

### 5- In vitro wound Healing potential of EPSR9 evidenced in the scratch assay.

EPSR9 exhibited significant vitro wound healing activity compared to control cells in the scratch assay. The table presents the mean wound area measurements at different time points (0h, 24h, and 48h) for EPSR9 and control cells. At the initial 0 h time point, the mean wound area was similar for both groups, with EPSR9 having a mean of 946.3333 $\mu m^2$ and control cells having a mean of 941.6667 $\mu m^2$. However, a significant difference emerged over 48 hours. The EPSR9 group exhibited a remarkable reduction in the mean wound area, decreasing from 946.3333 $\mu m^2$ at 0h to 258.6667 $\mu m^2$ at 48h. This corresponds to a 72.66% wound closure rate for the EPSR9 group. In contrast, the control group showed a more modest reduction in the mean wound area, decreasing from 941.6667 $\mu m^2$ at 0h to 387.0000 $\mu m^2$ at 48h, corresponding to a 58.90% wound closure rate (Table 4, Figure 5).

**Table 4.** Effect of EPSR9 on in vitro scratch assay wound closure over 48 hours.

| **Item** | **at 0h** | | **at 24h** | | **at 48 h** | | **RM µm/h** | **Wound closure %** | **Area difference um²** |
|---|---|---|---|---|---|---|---|---|---|
| | **Area** | **width** | **Area** | **Width** | **Area** | **Width** | | | |
| | 885 | 884.081 | 737 | 736.024 | 381 | 380.021 | | | |
| | 937 | 936.009 | 737 | 736 | 377 | 376.021 | | | |
| **Control cells** | 959 | 958.052 | 741 | 740.219 | 361 | 360.355 | | | |
| | 945 | 944.008 | 837 | 836.038 | 337 | 336.095 | | | |
| | 959 | 958 | 849 | 848.021 | 413 | 412 | | | |
| | 965 | 964 | 843 | 842.086 | 453 | 452.004 | | | |
| **mean** | 941.6667 | 940.6917 | 790.6667 | 789.7313 | 387 | 386.0827 | 11.55435 | 58.90265 | 554.6667 |
| | 941 | 940.009 | 755 | 754.13 | 309 | 308.104 | | | |
| | 937 | 936.002 | 767 | 766.094 | 281 | 280.029 | | | |
| **EPSR9** | 927 | 926.019 | 737 | 736.024 | 253 | 252.127 | | | |
| | 979 | 978.033 | 723 | 722.277 | 263 | 262.008 | | | |
| | 951 | 950.053 | 645 | 644.003 | 209 | 208.01 | | | |
| | 943 | 942.257 | 661 | 660.003 | 237 | 236.212 | | | |
| **mean** | 946.3333 | 945.3955 | 714.6667 | 713.7552 | 258.6667 | 257.7483 | 14.32598 | 72.66643 | 687.6667 |




**Figure 5.** Wound closure width at different time intervals (A) Untreated cells at 0 h (B) Treated cells with control after 48 h (C) Untreated cells at 0 h (D) Treated cells with EPSR9 after 48 h

### 6- Anti-obesity evaluation of EPSR9 through lipase in vitro inhibition

EPSR9 displayed concentration-dependent inhibition of lipase activity with an $IC_{50}$ of 107.73 µg/ml (Figure 6), while Orlistat had an $IC_{50}$ of 20.08 µg/ml. At the highest tested concentration of 1000 µg/ml, EPSR9 inhibited 83.8% lipase activity compared to 96.8% inhibition by Orlistat.




**Figure 6.** EPSR9 (1.9-1000µg/ml) inhibits pancreatic lipase dose independently compared to Orlistat. Mean ± SE (n = 3).

### 7- Antidiabetic in vitro inhibitory investigation of EPSR9

The experiment tested the in vitro inhibitory effects of the marine bacterial polysaccharide EPSR9 on α-amylase and α-glucosidase, two key enzymes involved in carbohydrate digestion and implicated in type 2 diabetes, in comparison to the standard drug Acarbose. EPSR9 exhibited concentration-dependent inhibition of both α-amylase ($IC_{50}$ 14.37 µg/ml) and α-glucosidase ($IC_{50}$ 26.73 µg/ml) (Figure). At the maximum tested concentration of 1000 µg/ml, EPSR9 inhibited α-amylase and α-glucosidase by 88.2% and 85.3%, respectively, compared to 82.1% and 96.1% for Acarbose at the same test concentration. In contrast, the standard Acarbose displayed $IC_{50}$ values of 50.93 µg/ml and 4.13 µg/ml for α-amylase and α-glucosidase inhibition, respectively.




**Figure 7.** Concentration-dependent α-amylase and α-glucosidase in vitro inhibition by EPSR9 (1.95 to 1000 µg/mL) vs the standard Acarbose (n=3, $p<0.05$, mean±SE, one-way ANOVA)

## 8- Antimicrobial screening of EPS

EPSR9 exhibited bactericidal activity against Gram-positive and Gram-negative bacteria, although it was more potent against the Gram-positive strains tested (Figure 8). Against the G-ve bacteria tested, EPSR9 showed moderate inhibitory activity. Against *E. coli*, it had an inhibition zone of 20mm compared to 16mm for gentamicin and MIC and MBC values of 125 and 250 µg/ml, respectively, giving an MBC/MIC ratio of 2, indicating a bactericidal effect. Against *K. pneumoniae*, the inhibition zone was 21mm vs 17mm for gentamicin, with high MIC and MBC values of 250 and 500 µg/ml and an MBC/MIC ratio of 1, indicating bactericidal potential. EPSR9 inhibited *Salmonella typhi* with an inhibition zone of 25mm compared to 24mm by gentamicin, and MIC and MBC of 31.25 and 62.5 µg/ml, respectively, with an MBC/MIC ratio of 2 confirming bactericidal action (Table 5, Figure 9).




**Figure 8.** The antibacterial effect of EPSR9 is represented as inhibition zones (mm) against ATCC G+ve and G-ve bacteria

Against the G+ve species, EPSR9 exhibited stronger antimicrobial properties. It inhibited *B. subtilis* with a zone of 25mm vs 23mm for gentamicin and MIC and MBC values of 31.25 and 62.5 µg/ml, giving a bactericidal MBC/MIC ratio of 2. Against *S. aureus*, the inhibition zone was 28mm for EPSR9 and 27mm for gentamicin, with MIC of 62.5 µg/ml and MBC of 125 µg/ml, also showing a bactericidal effect (MBC/MIC ratio 2). EPSR9 displayed potent activity against *E. faecalis*, with a 44mm inhibition zone compared to 30mm for gentamicin and very low MIC and MBC values of 3.9 and 7.8 µg/ml, respectively, confirming bactericidal potential via the MBC/MIC ratio of 2 (Table 5, Figure 9).

**Table 5**. Antibacterial potential of EPSR9 against G+ve and G-ve bacterial pathogens

| Pathogenic microorganisms | EPSR9 (mm) | Gentamicin (Control) | MIC (µg/ml) | MBC (µg/ml) | MBC/MIC Ratio |
|---|---|---|---|---|---|
| *Bacillus subtilis* (ATCC 6633) | 25±0.3 | 23±0.2 | 31.25 | 62.5 | 2 |
| *Staph.aureus* (ATCC 6538) | 28±0.1 | 27±0.3 | 62.5 | 125 | 2 |
| *Enterococcus faecalis* (ATCC 29212) | 44±0.4 | 30±0.4 | 3.9 | 7.8 | 2 |
| *Escherichia coli* (ATCC 8739) | 20±0.3 | 16±0.2 | 125 | 250 | 2 |

| | | | | | |
|---|---|---|---|---|---|
| *K. pneumoniae* (ATCC13883) | 21±0.3 | 17±0.2 | 250 | 250 | 1 |
| *Salmonella typhi* (ATCC 6539) | 25±0.1 | 24±0.3 | 31.25 | 62.5 | 2 |




**Figure 9.** Antibacterial effect of EPSR9 against ATCC G+ve and G-ve pathogenic bacteria

EPSR9 demonstrated more potent antimicrobial effects against gastric ulcer pathogenic *Helicobacter pylori*. It formed a larger inhibition zone of 24.67 mm compared to 21.00 mm for the positive control (amoxicillin at 0.05 mg/ml, clarithromycin at 0.05 mg/ml, and metronidazole at 0.8 mg/ml). EPSR9 also had a lower MIC of 31.25 µg/ml versus 62.5 µg/ml for the control. Both compounds showed an MBC of 62.5 µg/ml; however, EPSR9's MBC/MIC index was lower at 2. EPSR9 exhibited promising antibacterial activity against *H. pylori* in vitro, as evidenced by a larger inhibition zone, lower MIC, and comparable MBC to the positive control. Additionally, the anti-biofilm activity of different (sub-MBCs) of the EPSR9 against *H. pylori* biofilms was further tested. At 25% of the MBC, EPSR9 inhibited 89.51% of *H. pylori* biofilm formation. This activity increased to 92.75% inhibition at 50% of the MBC and 95.60% at 75% of the MBC.

**Table 6.** Antibacterial represented as inhibition zone (mm) and anti-biofilm activity at different MBC% of EPSR9 against *Helicobacter pylori*

| | Inhibition zone (mm) | MIC (µg/ml) | MBC (µg/ml) | MBC/MIC Index |
|---|---|---|---|---|
| **EPSR9** | 24.67 | 31.25 | 62.5 | 2 |
| **Positive Control** | 21.00 | 62.5 | 62.5 | 1 |



[A]



[B]

| EPSR9 / MBC% of *H. Pylori* | EPSR9 Anti- Biofilm Activity % |
|---|---|
| Blank (Media only) | |
| Media Organism(Cont.) | - |
| 25% of MBC | 89.51 |
| 50% of MBC | 92.75 |
| 75% of MBC | 95.60 |

Following this, the anti-biofilm activity of EPSR9 at various % MBC concentrations was tested against the same tested bacterial strains but not *E.coli* (Figure 10). First, the antibiofilm of G+ve bacteria was investigated. According to the findings, *S. aureus* showed the highest level of 67.28% anti-biofilm activity at 75% MBC. Meanwhile, at the lowest measured percentage of 25% MBC, its minimal activity was recorded at 37.06%. Additionally, *Enterococcus faecalis* showed a similar pattern, with its highest level of inhibition reaching 84.83% at 75% MBC (Table S3). Meanwhile, at 25% MBC, its activity dropped to 61.76%. Lastly, *Bacillus subtilis* was investigated and found to be most vulnerable at 75% MBC, where a remarkable 86.08% anti-biofilm effect occurred. However, when the concentration was reduced to 25% MBC, this dropped to 61.18% (Table 7).




**Figure 10.** Antibiofilm activity of EPSR9 against different G+ve and G-ve ATCC bacteria at different %MBC

Next, the evaluation of G-ve bacteria was conducted. Initially, *Klebsiella pneumoniae* showed 80.84% optimum activity at 75% MBC. At 25% MBC, this dropped to a smaller but still considerable of 50.86% (Table S3). Next, *Salmonella typhi* showed an even higher maximal inhibition of 88.05% at 75% MBC. Under less concentrated settings, it was less effective, declining to 61.90% at 25% MBC (Table 7). In general, EPSR9 outperformed all other pathogens at a maximum of 75% MBC. It also suppressed Gram-negative organisms more powerfully than Gram-positive ones. Essential insights into EPSR9's concentration-dependent anti-biofilm ability against a variety of therapeutically relevant bacteria were obtained from this thorough investigation. This comprehensive investigation emphasized the importance of EPSR9's concentration-dependent anti-biofilm abilities against pathogenic bacteria.

**Table 7.** EPSR9 Antibiofilm activity against *B.subtilis* and *S.typhi* at 25, 50, and 75% MBC

| **EPSR9 / MBC% of *B.subtilis*** | **Anti-biofilm %** |
|---|---|
| Blank (Media only) | |
| Media+Organism(Cont.) | - |
| 25% of MBC | 61.18 |
| 50% of MBC | 78.16 |
| 75% of MBC | 86.08 |
| **EPSR9 / MBC% of *S.typhi*** | **Anti-biofilm %** |



| | |
|---|---|
| Blank (Media only) | |
| Media+Organism(Cont.) | - |
| 25 % of MBC | 61.90 |
| 50% of MBC | 75.05 |
| 75% of MBC | 88.05 |

**Discussion**

Twelve bacterial isolates were isolated from Red Sea marine sand samples. These isolates were tested for exopolysaccharide biosynthesis. Marine bacterium strain R9 yielded the highest amounts of EPS (5.21g/l). Microbiological investigation revealed a Gram-positive, short rod-shaped bacterium with large white colonies (Table S1). Biochemical analyses indicated that it hydrolyzes starch, ferments carbohydrates, and is catalase-positive (Table S2). 16S rRNA sequencing with accession number (OR673614) identified it as *Bacillus rugosus* SYG20, validated by NCBI GenBank gene sequence matching (Figure 1).

Exopolysaccharide (EPSR9) has been extracted from *Bacillus rugosus* SYG20 because of its high yield (5.21g/L) and core fraction (86.01%) (Three volume $C_2H_5OH$). EPSR9 was shown to have uronic acid (45.33%), sulfate (9.98%), and N-acetyl glucose amine (5.40%) using FT-IR spectroscopy (Figure 2). EPSR9's monosaccharide fractions consisted of glucose, xylose, galacturonic acid, and arabinose in the following molar ratios by HPLC analysis: 2:3:1:1 (Figure 3).

Starting with antioxidant screening of EPSR9 by DPPH, TAC, and FRAP, as concentration increased from 1.95 to 1000 µg/ml, EPSR9 demonstrated dose-dependent and progressive DPPH radical scavenging from 20.0% to 92.5%, achieving 92.5% at the maximum concentration compared to 99.3% for ascorbic acid. The $IC_{50}$ value was 25.6 ± 0.001 µg/ml, while ascorbic acid was 2.52 ± 0.001 µg/ml (Figure 4). The TAC result utilizing the phosphomolybdenum technique was 417.77 AAE µg/ml, while The FRAP value for EPSR9 was 62.67 AAE µg/ml, compared to routine ascorbic acid (Table 1).

The antioxidative capacities of microbial EPSs have been spotted to be substantial. The structural elements of monosaccharides are categorized as reducing sugars due to their possession of aldoses and ketoses or their ability to undergo interconversion between these two forms. In addition, such capacity could be attributed to the diverse array of functional groups, such as -OH, -COOH,-$CONH_2$, -$SO4^{2-,}$ -SH,-$COCH_3$, -C=O, and many more. These functional groups exhibit the ability to donate electron pairs, undergo proton loss, or aid the process of metal binding. Consequently, free radicals become stable molecules [5,57]. Furthermore, it has been hypothesized that negatively charged

functional groups could generate an acidic environment, enhancing the hydrolysis of EPSs. Therefore, the augmentation of antioxidant activity is facilitated by a higher level of exposed hemiacetal hydroxyl groups [58].

Next, EPSR9 was tested as an anti-inflammatory natural compound by HRBCs-MSM assay. EPSR9 reduced inflammation. The dose-dependent suppression of hypotonic solution-induced erythrocyte hemolysis ranged from 81.8% to 99.0% at doses of 100-1000 μg/ml (Table 2). Indomethacin, a common anti-inflammatory medication, reduced HRBC lysis dose responsively from 93.3% to 99.5% at 100-1000 μg/ml. In the maximum concentration of 1000 μg/ml, EPSR9 showed similar anti-inflammatory effects to indomethacin (99% vs 99.5% inhibition), almost totally preventing hemolysis.

The anticoagulant property of EPSR9 was dose-dependent in vitro as evaluated by PT and PTT assays. EPSR9 increased PT from 18.7 to 49.3 seconds at 25-75 μg/ml, compared to 13 seconds for heparin. EPSR9 also dose-dependently elevated PTT from 33.5 to 60.3 seconds vs. 28 seconds for heparin. Heparin increased PT to 22.5-99.8 seconds and PTT to 66.1-145.7 seconds at the same doses. Although EPSR9 had less effective anticoagulant effects than heparin, it showed dose-responsive antithrombotic activity in both assays (Table 3).

The scratch experiment showed EPSR9 had substantial wound healing activity relative to control cells. EPSR9 treatment reduced wound area from 946.3333 $\mu m^2$ to 258.667 $\mu m^2$ in 48 hours, resulting in 72.66% closure. In comparison, control cells showed 58.90% wound closure, dropping from 941.66 $\mu m^2$ to 387 $\mu m^2$ (Table 4, Figure 5). Recent research indicates that EPSs generated by certain marine bacteria can promote wound healing by stimulating fibroblast and keratinocyte migration and proliferation, documenting the bioactivities of such molecules and their potential usage as wound-care products [28,59,60]. *Synechocystis aquatilis* Sauvageau B90.79 synthesized sulfated EPS that acted as an anticoagulant and a complement modulator [61]. Anticoagulant action was observed in the EPS derived from *Alteromonas infernus* after chemical modifications involving sulfation and depolymerization[62]. Shirzad et al. documented the anti-elastase, anticollagenase, antioxidant, and wound-healing properties of EPSs synthesized by certain strains of *Lactobacilli*. These EPSs can potentially be developed into suitable agents for combating skin aging [63].

Moving to the anti-obesity evaluation of EPSR9 through lipase in vitro inhibition, EPSR9 showed concentration-dependent inhibition of lipase activity with an $IC_{50}$ of 107.73 μg/ml. In comparison, Orlistat had an $IC_{50}$ of 20.08 μg/ml. At 1000 μg/ml, EPSR9 inhibited 83.8% lipase activity compared to 96.8% inhibition by Orlistat (Figure 6). The EPSs generated by *Lactobacillus plantarum*

GA06 and GA11 exhibited in vitro cholesterol reduction efficiencies of 36.7% and 28.6%, respectively. The observed EPSs showed a notable capacity for cholesterol binding [64]. Another in vitro study of an EPS (EPS400) from *Limosilactobacillus fermentum* NCDC400 exhibited a significant cholesterol-lowering efficacy of 90.32% [65]. One notable characteristic of the EPS generated by *Leuconostoc mesenteroides* LM187 is its considerable capacity to reduce cholesterol levels, with an efficacy rate of 53% [66].

Next, EPSR9 was compared to Acarbose for its inhibitory effects on α-amylase and α-glucosidase. EPSR9 inhibited α-amylase ($IC_{50}$ 14.37 µg/ml) and α-glucosidase ($IC_{50}$ 26.73 µg/ml) concentration-dependent at 1000 µg/ml, EPSR9 inhibited enzymes by 88.2% and 85.3%, compared to 82.1% and 96.1% for Acarbose (Figure 7). Acarbose's $IC_{50}$ values were 50.93 µg/ml and 4.13 µg/ml for both enzymes. EPSR9 exhibits a modest inhibitory effect against carbohydrate-digesting enzymes in vitro and requires additional investigation in diabetes animal models to understand its antidiabetic efficacy and mechanism of action.

The antidiabetic property is regarded as one of the activities demonstrated by microbial EPSs, which may be measured by evaluating the inhibition of α-amylase and α-glucosidase enzymes. This inhibitory mechanism that impedes the hydrolysis of glucose confers advantages to individuals with diabetes. Following our findings, EPS derived from *Enterococcus faecium* MS79 exhibited 91% and 92% inhibitory activity against α-amylase and α-glucosidase, respectively [67]. EPSs derived from marine cyanobacteria have been reported to have antidiabetic properties via blocking α-glucosidase. *Pseudanabaena* and *Chroococcus* sp. extracted EPS reduced α-glucosidase activity by 14.02% and 13.00%, respectively [68].

The mechanism by which EPS inhibits α-amylase and α-glucosidase is not clearly understood. EPS appears to inhibit hydrolysis via binding to the active site of enzymes or substrates. Another assumption is that EPS reduces glucose levels by activating insulin receptors and increasing glucose utilization [69]. The hypoglycemic influence of EPS could also be attributed to its ability to stimulate Langerhans islets, enhance peripheral sensitivity to residual insulin, and its antioxidant potency [70,71].

Then, EPSR9 was tested against a spectrum of G+ve and G-ve pathogenic ATCC bacteria. EPSR9's effectiveness against G+ve bacteria was more pronounced (Figure 8, 9). Inhibition zones for *E. Coli* were 20 mm for EPSR9 and 16 mm for gentamicin; corresponding MIC/MBC values were 125/250 µg/ml. Zones against *K. pneumoniae* were 21 mm compared to 17 mm, and the MIC and MBC were 250 and 500 µg/ml, respectively. *S. typhi* zones were 25 mm vs. 24 mm; MIC/MBC 32.25/62.5 µg/ml. The *B. subtilis* zones measured 25 vs 23 mm, with a MIC/MBC of 31.25/62.5 µg/ml. The *S.*

*aureus* zones measured 28 mm vs 27 mm, with a MIC/MBC of 62.5/125 µg/ml. With a zone of 44 mm vs 30 mm, EPSR9 significantly inhibited *E. faecalis*; MIC/MBC 3.9/7.8 µg/ml (Table 5). EPSR9 showed improved efficacy against Gram-positive bacteria, substantially suppressing *E. faecalis*. The evidence highlights the intriguing antibacterial potential of EPSR9 and calls for more research into it as a cutting-edge antibacterial drug.

Against *H. pylori*, EPSR9 showed more potent antibacterial activity. Compared to the positive control, which had an inhibition zone of 21.00 mm, it generated a larger one of 24.67 mm (Table 6). Additionally, EPSR9's MIC was lower, 31.25 µg/ml, than the control's, which was 62.5 µg/ml. EPSR9's MBC/MIC value was lower at 2; however, both compounds displayed an MBC of 62.5 µg/ml. EPSR9 had encouraging antibacterial activity against *H. pylori* in vitro, as shown by an extended inhibitory zone, a lower MIC, and an MBC similar to the positive control.

EPSR9's efficacy as an anti-biofilm agent was tested against the same bacterial spectrum except for *E. coli* (Figure 10). When tested against gram-positive bacteria, *S. aureus* had the highest activity, 67.28% at 75% MBC—lowering at 25% MBC to 37.06% (Table S3). The highest percentage of *E. faecalis* was 84.83% at 75% MBC, and the lowest rate was 61.76% at 25% MBC (Table S3). The most vulnerable strain was *B. subtilis*, which declined to 61.18% at 25% MBC from 86.08% at 75% MBC (Table 7). Within gram-negatives, *K. pneumoniae* did the best, with an 80.84% highest inhibition rate at 75% MBC and a 50.86% lowest antibiofilm rate at 25% MBC (Table S3). At 75% MBC, *S. typhi* was inhibited up to 88.05%, but it decreased to 61.90% at 25% MBC. In general, EPSR9 was more effective against gram-negative bacteria than gram-positive bacteria at 75% MBC (Table 7).

Sub-MBCs of EPSR9 were then examined for their ability to disintegrate down *H. pylori* biofilms. At 25% of the MBC, EPSR9 exhibited strong anti-biofilm efficacy, preventing 89.51% of *H. pylori* biofilm formation. At 75% of the MBC, the anti-biofilm activity reached 95.60% inhibition after increasing in a dose-dependent manner. EPSR9 exhibited antibacterial solid and anti-biofilm properties against *H. pylori* at concentrations lower than its MBC, and at 75% of MBC, it nearly completely (95.60%) inhibited biofilm formation (Table 6).

The antibacterial responses of microbial EPSs are potentially associated with disrupting the structural integrity of bacterial cell membranes, cell walls, and respiratory chains, hence impacting the machinery involved in cell division [72,73]. Microbial EPSs cannot permeate cell membranes, thus exerting their antibacterial effects, likely through their interaction with oligopeptides or acyl-homoserine lactones in G+ve and G-ve bacteria.

The chemicals mentioned above are signal molecules associated with biofilm formation. Cell communication disruption and biofilm development suppression are observed due to EPSs acting through this mechanism [74]. Hence, it is plausible to consider such EPSs as potentially efficacious therapeutic agents for mitigating chronic and recurrent infections associated with biofilms.

Moreover, EPSs have been observed to diminish the autoaggregation of bacterial pathogens, rendering them more vulnerable to the immune response within the host [75]. Additionally, EPSs can adhere to microbial pathogens using their EPS. The coaggregation process enhances these entities' antibacterial potential by obstructing the receptors or channels on Gram-negative pathogenic bacteria's outer membrane [76]. Since EPSs exhibit a diverse array of functional groups, encompassing hydroxyl, phosphate, and carbonyl units. Therefore, there has been a proposition indicating that these functional groups play a part in how bacterial pathogens interact with their cell walls or membranes. Such interaction may elucidate the antimicrobial attributes [77].

Forming biofilms is intricately associated with the colonization and dissemination of pathogenic bacteria. These factors significantly influence the virulence of pathogens, intercellular communication processes, and many infection states. A potential in vitro mechanism behind the observed antibiofilm action of EPSR9 derived by *Bacillus rugosus* SYG20 could involve the disruption of cell-to-cell communication. This disruption may occur through the binding of EPSR9 to glycocalyx receptors located on the surface of pathogenic bacteria or interfering with the signal molecules associated with biofilm formation. Consequently, this generation of biofilms is impeded, leading to the eventual exertion of the antimicrobial effect.

The molecular structure of EPSR9 needs to be verified, and further research is required to investigate the compound's biocompatibility in vivo, its precise mode of action, and whether or not it can alter the composition of the gut microbiome. Further, genetic engineering strategies like mutagenic strains and gene alterations can expand the number of marine bacterial strains that biosynthesize valuable EPSs with unique structures and bioactivities to achieve increased EPS yields.

## Conclusion

The present investigation isolated, extracted, and characterized a bioactive bacterial exopolysaccharide (EPSR9) synthesized by the marine bacterium *Bacillus rugosus* SYG20 and comprehensively demonstrated its remarkable pharmaceutical potential through extensive in vitro assessments. EPSR9 exhibited potent antioxidant, anti-inflammatory, and anticoagulant properties and significant wound healing, anti-obesity, and antidiabetic activities. Notably, EPSR9 displayed broad-spectrum bactericidal effects against Gram-positive and Gram-negative pathogens, including

*Helicobacter pylori*, and exhibited potent anti-biofilm activity, effectively disrupting the formation of bacterial biofilms. These comprehensive findings underscore the immense therapeutic promise of this marine-derived exopolysaccharide, which could serve as a valuable natural compound for developing multifunctional therapeutic agents.

## Notes

The authors declare no conflict of interest.


## Acknowledgments

The authors thank the Princess Nourah bint Abdulrahman University Researchers Supporting Project number (PNURSP2024R182), Princess Nourah bint Abdulrahman University, Riyadh, Saudi Arabia. Also, this study is supported via funding from Prince Sattam bin Abdulaziz University, Alkharj, Saudi Arabia, project number (PSAU/2024/R/1445).




## References


1. Dolbeth, M.; Arenas, F. Marine Ecosystems: Types, Their Importance and Main Impacts. In *Life Below Water*; Leal Filho, W., Azul, A.M., Brandli, L., Lange Salvia, A., Wall, T., Eds.; Springer International Publishing: Cham, 2020; pp. 1–17 ISBN 978-3-319-71064-8.
2. Baria, D.M.; Patel, N.Y.; Yagnik, S.M.; Panchal, R.R.; Rajput, K.N.; Raval, V.H. Exopolysaccharides from Marine Microbes with Prowess for Environment Cleanup. *Environ. Sci. Pollut. Res.* **2022**, *29*, 76611–76625, doi:10.1007/s11356-022-23198-z.
3. Casillo, A.; Lanzetta, R.; Parrilli, M.; Corsaro, M.M. Exopolysaccharides from Marine and Marine Extremophilic Bacteria: Structures, Properties, Ecological Roles and Applications. *Mar. Drugs* **2018**, *16*, 69, doi:10.3390/md16020069.
4. Qamar, S.A.; Riasat, A.; Jahangeer, M.; Fatima, R.; Bilal, M.; Iqbal, H.M.N.; Mu, B.-Z. Prospects of Microbial Polysaccharides-Based Hybrid Constructs for Biomimicking Applications. *J. Basic Microbiol.* **2022**, *62*, 1319–1336, doi:10.1002/jobm.202100596.
5. Andrew, M.; Jayaraman, G. Structural Features of Microbial Exopolysaccharides in Relation to Their Antioxidant Activity. *Carbohydr. Res.* **2020**, *487*, 107881, doi:10.1016/j.carres.2019.107881.
6. Tabernero, A.; Cardea, S. Microbial Exopolysaccharides as Drug Carriers. *Polymers* **2020**, *12*, 2142, doi:10.3390/polym12092142.
7. Wang, J.; Salem, D.R.; Sani, R.K. Extremophilic Exopolysaccharides: A Review and New Perspectives on Engineering Strategies and Applications. *Carbohydr. Polym.* **2019**, *205*, 8–26, doi:10.1016/j.carbpol.2018.10.011.
8. Manivasagan, P.; Kim, S.-K. Extracellular Polysaccharides Produced by Marine Bacteria. *Adv. Food Nutr. Res.* **2014**, *72*, 79–94, doi:10.1016/B978-0-12-800269-8.00005-1.
9. Suresh Kumar, A.; Mody, K.; Jha, B. Bacterial Exopolysaccharides – a Perception. *J. Basic Microbiol.* **2007**, *47*, 103–117, doi:10.1002/jobm.200610203.
10. Poli, A.; Anzelmo, G.; Nicolaus, B. Bacterial Exopolysaccharides from Extreme Marine Habitats: Production, Characterization and Biological Activities. *Mar. Drugs* **2010**, *8*, 1779–1802, doi:10.3390/md8061779.

11. Kaur, N.; Dey, P. Bacterial Exopolysaccharides as Emerging Bioactive Macromolecules: From Fundamentals to Applications. *Res. Microbiol.* **2023**, *174*, 104024, doi:10.1016/j.resmic.2022.104024.
12. Prasad, S.; Purohit, S.R. Microbial Exopolysaccharide: Sources, Stress Conditions, Properties and Application in Food and Environment: A Comprehensive Review. *Int. J. Biol. Macromol.* **2023**, *242*, 124925, doi:10.1016/j.ijbiomac.2023.124925.
13. Sun, X.; Zhang, J. Bacterial Exopolysaccharides: Chemical Structures, Gene Clusters and Genetic Engineering. *Int. J. Biol. Macromol.* **2021**, *173*, 481–490, doi:10.1016/j.ijbiomac.2021.01.139.
14. Ibrahim, H.A.H.; Abou Elhassayeb, H.E.; El-Sayed, W.M.M. Potential Functions and Applications of Diverse Microbial Exopolysaccharides in Marine Environments. *J. Genet. Eng. Biotechnol.* **2022**, *20*, 151, doi:10.1186/s43141-022-00432-2.
15. Jenab, A.; Roghanian, R.; Emtiazi, G. Bacterial Natural Compounds with Anti-Inflammatory and Immunomodulatory Properties (Mini Review). *Drug Des. Devel. Ther.* **2020**, *14*, 3787–3801, doi:10.2147/DDDT.S261283.
16. Tarannum, N.; Hossain, T.J.; Ali, F.; Das, T.; Dhar, K.; Nafiz, I.H. Antioxidant, Antimicrobial and Emulsification Properties of Exopolysaccharides from Lactic Acid Bacteria of Bovine Milk: Insights from Biochemical and Genomic Analysis. *LWT* **2023**, *186*, 115263, doi:10.1016/j.lwt.2023.115263.
17. Angelin, J.; Kavitha, M. Exopolysaccharides from Probiotic Bacteria and Their Health Potential. *Int. J. Biol. Macromol.* **2020**, *162*, 853–865, doi:10.1016/j.ijbiomac.2020.06.190.
18. Wu, J.; Zhang, Y.; Ye, L.; Wang, C. The Anti-Cancer Effects and Mechanisms of Lactic Acid Bacteria Exopolysaccharides *in Vitro*: A Review. *Carbohydr. Polym.* **2021**, *253*, 117308, doi:10.1016/j.carbpol.2020.117308.
19. Netrusov, A.I.; Liyaskina, E.V.; Kurgaeva, I.V.; Liyaskina, A.U.; Yang, G.; Revin, V.V. Exopolysaccharides Producing Bacteria: A Review. *Microorganisms* **2023**, *11*, 1541, doi:10.3390/microorganisms11061541.
20. Selim, S.; Almuhayawi, M.S.; Alharbi, M.T.; Nagshabandi, M.K.; Alanazi, A.; Warrad, M.; Hagagy, N.; Ghareeb, A.; Ali, A.S. In Vitro Assessment of Antistaphylococci, Antitumor, Immunological and Structural Characterization of Acidic Bioactive Exopolysaccharides from Marine Bacillus Cereus Isolated from Saudi Arabia. *Metabolites* **2022**, *12*, 132, doi:10.3390/metabo12020132.
21. Alharbi, N.K.; Azeez, Z.F.; Alhussain, H.M.; Shahlol, A.M.A.; Albureikan, M.O.I.; Elsehrawy, M.G.; Aloraini, G.S.; El-Nablaway, M.; Khatrawi, E.M.; Ghareeb, A. Tapping the Biosynthetic Potential of Marine Bacillus Licheniformis LHG166, a Prolific Sulphated Exopolysaccharide Producer: Structural Insights, Bio-Prospecting Its Antioxidant, Antifungal, Antibacterial and Anti-Biofilm Potency as a Novel Anti-Infective Lead. *Front. Microbiol.* **2024**, *15*, doi:10.3389/fmicb.2024.1385493.
22. Abdel-Wahab, B.A.; F. Abd El-Kareem, H.; Alzamami, A.; A. Fahmy, C.; H. Elesawy, B.; Mostafa Mahmoud, M.; Ghareeb, A.; El Askary, A.; H. Abo Nahas, H.; G. M. Attallah, N.; et al. Novel Exopolysaccharide from Marine Bacillus Subtilis with Broad Potential Biological Activities: Insights into Antioxidant, Anti-Inflammatory, Cytotoxicity, and Anti-Alzheimer Activity. *Metabolites* **2022**, *12*, 715, doi:10.3390/metabo12080715.
23. Alshawwa, S.Z.; Alshallash, K.S.; Ghareeb, A.; Elazzazy, A.M.; Sharaf, M.; Alharthi, A.; Abdelgawad, F.E.; El-Hossary, D.; Jaremko, M.; Emwas, A.-H.; et al. Assessment of Pharmacological Potential of Novel Exopolysaccharide Isolated from Marine Kocuria Sp. Strain AG5: Broad-Spectrum Biological Investigations. *Life* **2022**, *12*, 1387, doi:10.3390/life12091387.
24. Alharbi, M.A.; Alrehaili, A.A.; Albureikan, M.O.I.; Gharib, A.F.; Daghistani, H.; Bakhuraysah, M.M.; Aloraini, G.S.; Bazuhair, M.A.; Alhuthali, H.M.; Ghareeb, A. In Vitro Studies on the Pharmacological Potential, Anti-Tumor, Antimicrobial, and Acetylcholinesterase Inhibitory Activity of Marine-Derived Bacillus Velezensis AG6 Exopolysaccharide. *RSC Adv.* **2023**, *13*, 26406–26417, doi:10.1039/D3RA04009G.
25. Aloraini, G.S.; Albureikan, M.O.I.; Shahlol, A.M.A.; Shamrani, T.; Daghistani, H.; El-Nablaway, M.; Tharwat, N.A.; Elazzazy, A.M.; Basyony, A.F.; Ghareeb, A. Biomedical and Therapeutic Potential of Marine-Derived Pseudomonas Sp. Strain AHG22 Exopolysaccharide: A Novel Bioactive Microbial Metabolite. *Rev. Adv. Mater. Sci.* **2024**, *63*, doi:10.1515/rams-2024-0016.
26. Kant Bhatia, S.; Gurav, R.; Choi, Y.-K.; Choi, T.-R.; Kim, H.-J.; Song, H.-S.; Mi Lee, S.; Lee Park, S.; Soo Lee, H.; Kim, Y.-G.; et al. Bioprospecting of Exopolysaccharide from Marine Sphingobium Yanoikuyae BBL01:

Production, Characterization, and Metal Chelation Activity. *Bioresour. Technol.* **2021**, *324*, 124674, doi:10.1016/j.biortech.2021.124674.
27. Sahana, T.G.; Rekha, P.D. A Bioactive Exopolysaccharide from Marine Bacteria Alteromonas Sp. PRIM-28 and Its Role in Cell Proliferation and Wound Healing in Vitro. *Int. J. Biol. Macromol.* **2019**, *131*, 10–18, doi:10.1016/j.ijbiomac.2019.03.048.
28. Sahana, T.G.; Rekha, P.D. A Novel Exopolysaccharide from Marine Bacterium Pantoea Sp. YU16-S3 Accelerates Cutaneous Wound Healing through Wnt/β-Catenin Pathway. *Carbohydr. Polym.* **2020**, *238*, 116191, doi:10.1016/j.carbpol.2020.116191.
29. Dhahri, M.; Sioud, S.; Dridi, R.; Hassine, M.; Boughattas, N.A.; Almulhim, F.; Al Talla, Z.; Jaremko, M.; Emwas, A.-H.M. Extraction, Characterization, and Anticoagulant Activity of a Sulfated Polysaccharide from Bursatella Leachii Viscera. *ACS Omega* **2020**, *5*, 14786–14795, doi:10.1021/acsomega.0c01724.
30. Du, Z.; Jia, X.; Chen, J.; Zhou, S.; Chen, J.; Liu, X.; Cao, X.; Zhong, S.; Hong, P. Isolation and Characterization of a Heparin-Like Compound with Potent Anticoagulant and Fibrinolytic Activity from the Clam Coelomactra Antiquata. *Mar. Drugs* **2019**, *18*, 6, doi:10.3390/md18010006.
31. Yang, W.; Chen, D.; He, Z.; Zhou, L.; Cai, Y.; Mao, H.; Gao, N.; Zuo, Z.; Yin, R.; Zhao, J. NMR Characterization and Anticoagulant Activity of the Oligosaccharides from the Fucosylated Glycosaminoglycan Isolated from Holothuria Coluber. *Carbohydr. Polym.* **2020**, *233*, 115844, doi:10.1016/j.carbpol.2020.115844.
32. Brito, A.S.; Arimatéia, D.S.; Souza, L.R.; Lima, M.A.; Santos, V.O.; Medeiros, V.P.; Ferreira, P.A.; Silva, R.A.; Ferreira, C.V.; Justo, G.Z.; et al. Anti-Inflammatory Properties of a Heparin-like Glycosaminoglycan with Reduced Anti-Coagulant Activity Isolated from a Marine Shrimp. *Bioorg. Med. Chem.* **2008**, *16*, 9588–9595, doi:10.1016/j.bmc.2008.09.020.
33. Liu, X.; Zhang, X.; Xiao, Y.; Gao, T.; Wang, G.; Wang, Z.; Zhang, Z.; Hu, Y.; Dong, Q.; Zhao, S.; et al. Heparin-Induced Thrombocytopenia Is a High Risk of Mortality in Critical COVID-19 Patients Receiving Heparin-Involved Treatment 2020.
34. Rcr, O.; Rr, A.; Ta, G. A Review of Plant Sulfated Polysaccharides and Their Relations with Anticoagulant Activities. *J. Dev. Drugs* **2016**, *05*, doi:10.4172/2329-6631.1000166.
35. Tang, L.; Chen, Y.; Jiang, Z.; Zhong, S.; Chen, W.; Zheng, F.; Shi, G. Purification, Partial Characterization and Bioactivity of Sulfated Polysaccharides from Grateloupia Livida. *Int. J. Biol. Macromol.* **2017**, *94*, 642–652, doi:10.1016/j.ijbiomac.2016.10.067.
36. Hayakawa, M.; Nonomura, H. Humic Acid-Vitamin Agar, a New Medium for the Selective Isolation of Soil Actinomycetes. *J. Ferment. Technol.* **1987**, *65*, 501–509, doi:10.1016/0385-6380(87)90108-7.
37. Tamura, K.; Peterson, D.; Peterson, N.; Stecher, G.; Nei, M.; Kumar, S. MEGA5: Molecular Evolutionary Genetics Analysis Using Maximum Likelihood, Evolutionary Distance, and Maximum Parsimony Methods. *Mol. Biol. Evol.* **2011**, *28*, 2731–2739, doi:10.1093/molbev/msr121.
38. Liu, C.; Lu, J.; Lu, L.; Liu, Y.; Wang, F.; Xiao, M. Isolation, Structural Characterization and Immunological Activity of an Exopolysaccharide Produced by Bacillus Licheniformis 8-37-0-1. *Bioresour. Technol.* **2010**, *101*, 5528–5533, doi:10.1016/j.biortech.2010.01.151.
39. Wang, H.; Jiang, X.; Mu, H.; Liang, X.; Guan, H. Structure and Protective Effect of Exopolysaccharide from P. Agglomerans Strain KFS-9 against UV Radiation. *Microbiol. Res.* **2007**, *162*, 124–129, doi:10.1016/j.micres.2006.01.011.
40. Nicely, W.B. Infrared Spectra of Carbohydrates. In *Advances in Carbohydrate Chemistry*; Wolfrom, M.L., Tipson, R.S., Eds.; Academic Press, 1957; Vol. 12, pp. 13–33.
41. Filisetti-Cozzi, T.M.; Carpita, N.C. Measurement of Uronic Acids without Interference from Neutral Sugars. *Anal. Biochem.* **1991**, *197*, 157–162, doi:10.1016/0003-2697(91)90372-z.
42. Garrido, M.L. Determination of Sulphur in Plant Material. *Analyst* **1964**, *89*, 61–66, doi:10.1039/AN9648900061.
43. Randall, R.C.; Phillips, G.O.; Williams, P.A. Fractionation and Characterization of Gum from Acacia Senegal. *Food Hydrocoll.* **1989**, *3*, 65–75, doi:10.1016/S0268-005X(89)80034-7.
44. Brand-Williams, W.; Cuvelier, M.E.; Berset, C. Use of a Free Radical Method to Evaluate Antioxidant Activity. *LWT - Food Sci. Technol.* **1995**, *28*, 25–30, doi:10.1016/S0023-6438(95)80008-5.

45. Prieto, P.; Pineda, M.; Aguilar, M. Spectrophotometric Quantitation of Antioxidant Capacity through the Formation of a Phosphomolybdenum Complex: Specific Application to the Determination of Vitamin E. *Anal. Biochem.* **1999**, *269*, 337–341, doi:10.1006/abio.1999.4019.
46. Lahmass, I.; Ouahhoud, S.; Elmansuri, M.; Sabouni, A.; Mohammed, E.; Benabbas, R.; Choukri, M.; Saalaoui, E. Determination of Antioxidant Properties of Six By-Products of Crocus Sativus L. (Saffron) Plant Products. *Waste Biomass Valorization* **2018**, *9*, doi:10.1007/s12649-017-9851-y.
47. Benzie, I.F.; Strain, J.J. The Ferric Reducing Ability of Plasma (FRAP) as a Measure of "Antioxidant Power": The FRAP Assay. *Anal. Biochem.* **1996**, *239*, 70–76, doi:10.1006/abio.1996.0292.
48. Anosike, C.A.; Obidoa, O.; Ezeanyika, L.U. Membrane Stabilization as a Mechanism of the Anti-Inflammatory Activity of Methanol Extract of Garden Egg (Solanum Aethiopicum). *Daru J. Fac. Pharm. Tehran Univ. Med. Sci.* **2012**, *20*, 76, doi:10.1186/2008-2231-20-76.
49. Fan, L.; Wu, P.; Zhang, J.; Gao, S.; Wang, L.; Li, M.; Sha, M.; Xie, W.; Nie, M. Synthesis and Anticoagulant Activity of the Quaternary Ammonium Chitosan Sulfates. *Int. J. Biol. Macromol.* **2012**, *50*, 31–37, doi:10.1016/j.ijbiomac.2011.09.024.
50. Martinotti, S.; Ranzato, E. Scratch Wound Healing Assay. In *Methods in molecular biology (Clifton, N.J.)*; 2019; Vol. 2109 ISBN 978-1-07-160250-8.
51. Roh, C.; Jung, U. Screening of Crude Plant Extracts with Anti-Obesity Activity. *Int. J. Mol. Sci.* **2012**, *13*, 1710–1719, doi:10.3390/ijms13021710.
52. Wickramaratne, M.N.; Punchihewa, J.C.; Wickramaratne, D.B.M. In-Vitro Alpha Amylase Inhibitory Activity of the Leaf Extracts of Adenanthera Pavonina. *BMC Complement. Altern. Med.* **2016**, *16*, 466, doi:10.1186/s12906-016-1452-y.
53. Pistia-Brueggeman, G.; Hollingsworth, R.I. A Preparation and Screening Strategy for Glycosidase Inhibitors. *Tetrahedron* **2001**, *57*, 8773–8778, doi:10.1016/S0040-4020(01)00877-8.
54. Magaldi, S.; Mata-Essayag, S.; Hartung de Capriles, C.; Perez, C.; Colella, M.T.; Olaizola, C.; Ontiveros, Y. Well Diffusion for Antifungal Susceptibility Testing. *Int. J. Infect. Dis. IJID Off. Publ. Int. Soc. Infect. Dis.* **2004**, *8*, 39–45, doi:10.1016/j.ijid.2003.03.002.
55. Brown, W.J. National Committee for Clinical Laboratory Standards Agar Dilution Susceptibility Testing of Anaerobic Gram-Negative Bacteria. *Antimicrob. Agents Chemother.* **1988**, *32*, 385–390.
56. Antunes, A.L.S.; Trentin, D.S.; Bonfanti, J.W.; Pinto, C.C.F.; Perez, L.R.R.; Macedo, A.J.; Barth, A.L. Application of a Feasible Method for Determination of Biofilm Antimicrobial Susceptibility in Staphylococci. *APMIS Acta Pathol. Microbiol. Immunol. Scand.* **2010**, *118*, 873–877, doi:10.1111/j.1600-0463.2010.02681.x.
57. Lin, B.; Huang, G. An Important Polysaccharide from Fermentum. *Food Chem. X* **2022**, *15*, 100388, doi:10.1016/j.fochx.2022.100388.
58. Zhou, S.; Huang, G.; Huang, H. Extraction, Derivatization and Antioxidant Activities of Onion Polysaccharide. *Food Chem.* **2022**, *388*, 133000, doi:10.1016/j.foodchem.2022.133000.
59. Sun, M.-L.; Zhao, F.; Chen, X.-L.; Zhang, X.-Y.; Zhang, Y.-Z.; Song, X.-Y.; Sun, C.-Y.; Yang, J. Promotion of Wound Healing and Prevention of Frostbite Injury in Rat Skin by Exopolysaccharide from the Arctic Marine Bacterium Polaribacter Sp. SM1127. *Mar. Drugs* **2020**, *18*, 48, doi:10.3390/md18010048.
60. Zaghloul, E.H.; Ibrahim, M.I.A. Production and Characterization of Exopolysaccharide From Newly Isolated Marine Probiotic Lactiplantibacillus Plantarum EI6 With in Vitro Wound Healing Activity. *Front. Microbiol.* **2022**, *13*.
61. Volk, R.-B.; Venzke, K.; Blaschek, W.; Alban, S. Complement Modulating and Anticoagulant Effects of a Sulfated Exopolysaccharide Released by the Cyanobacterium Synechocystis Aquatilis. *Planta Med.* **2006**, *72*, 1424–1427, doi:10.1055/s-2006-951707.
62. S, C.J.; L, C.; D, H.; J, R.; A, B.; C, S.; O, R.; Am, F. Characterization, Chemical Modifications and in Vitro Anticoagulant Properties of an Exopolysaccharide Produced by Alteromonas Infernus. *Biochim. Biophys. Acta* **2001**, *1528*, doi:10.1016/s0304-4165(01)00185-4.
63. Shirzad, M.; Hamedi, J.; Motevaseli, E.; Modarressi, M.H. Anti-Elastase and Anti-Collagenase Potential of Lactobacilli Exopolysaccharides on Human Fibroblast. *Artif. Cells Nanomedicine Biotechnol.* **2018**, *46*, 1051–1061, doi:10.1080/21691401.2018.1443274.

64. Avci, G.A.; Cagatay, G.; Cilak, G.O.; Avci, E. PROBABLE NOVEL PROBIOTICS: EPS PRODUCTION, CHOLESTEROL REMOVAL AND GLYCOCHOLATE DECONJUGATION OF LACTOBACILLUS PLANTARUM GA06 AND GA11 ISOLATED FROM LOCAL HANDMADE- CHEESE. *J. Microbiol. Biotechnol. Food Sci.* **2020**, *10*, 83–86, doi:10.15414/jmbfs.2020.10.1.83-86.
65. Gawande, K.; Kolhekar, M.; Kumari, M.; Kapila, S.; Sharma, P.; Ali, S.A.; Behare, P.V. Lactic Acid Bacteria Based Purified Exopolysaccharide Showed Viscofying and Hypercholesterolemic Capabilites. *Food Hydrocoll. Health* **2021**, *1*, 100042, doi:10.1016/j.fhfh.2021.100042.
66. Zhang, Q.; Wang, J.; Sun, Q.; Zhang, S.-M.; Sun, X.-Y.; Li, C.-Y.; Zheng, M.-X.; Xiang, W.-L.; Tang, J. Characterization and Antioxidant Activity of Released Exopolysaccharide from Potential Probiotic Leuconostoc Mesenteroides LM187. *J. Microbiol. Biotechnol.* **2021**, *31*, 1144–1153, doi:10.4014/jmb.2103.03055.
67. Ayyash, M.; Stathopoulos, C.; Abu-Jdayil, B.; Esposito, G.; Baig, M.; Turner, M.S.; Baba, A.S.; Apostolopoulos, V.; Al-Nabulsi, A.; Osaili, T. Exopolysaccharide Produced by Potential Probiotic Enterococcus Faecium MS79: Characterization, Bioactivities and Rheological Properties Influenced by Salt and pH. *LWT* **2020**, *131*, 109741, doi:10.1016/j.lwt.2020.109741.
68. Priatni, S.; Budiwati, T.A.; Ratnaningrum, D.; Kosasih, W.; Andryani, R.; Susanti, H.; Susilaningsih, D. Antidiabetic Screening of Some Indonesian Marine Cyanobacteria Collection. *Biodiversitas J. Biol. Divers.* **2016**, *17*, doi:10.13057/biodiv/d170236.
69. Ding, X.; Zhang, J.; Jiang, P.; Xu, X.; Liu, Z. Structural Features and Hypoglycaemic Activity of an Exopolysaccharide Produced by Sorangium Cellulosum. *Lett. Appl. Microbiol.* **2004**, *38*, 223–228, doi:10.1111/j.1472-765x.2004.01465.x.
70. Dahech, I.; Belghith, K.S.; Hamden, K.; Feki, A.; Belghith, H.; Mejdoub, H. Antidiabetic Activity of Levan Polysaccharide in Alloxan-Induced Diabetic Rats. *Int. J. Biol. Macromol.* **2011**, *49*, 742–746, doi:10.1016/j.ijbiomac.2011.07.007.
71. Ghoneim, M.A.M.; Hassan, A.I.; Mahmoud, M.G.; Asker, M.S. Effect of Polysaccharide from Bacillus Subtilis Sp. on Cardiovascular Diseases and Atherogenic Indices in Diabetic Rats. *BMC Complement. Altern. Med.* **2016**, *16*, 112, doi:10.1186/s12906-016-1093-1.
72. Hasheminya, S.-M.; Dehghannya, J. Novel Ultrasound-Assisted Extraction of Kefiran Biomaterial, a Prebiotic Exopolysaccharide, and Investigation of Its Physicochemical, Antioxidant and Antimicrobial Properties. *Mater. Chem. Phys.* **2020**, *243*, 122645, doi:10.1016/j.matchemphys.2020.122645.
73. Hu, Y.-Q.; Wei, W.; Gao, M.; Zhou, Y.; Wang, G.-X.; Zhang, Y. Effect of Pure Oxygen Aeration on Extracellular Polymeric Substances (EPS) of Activated Sludge Treating Saline Wastewater. *Process Saf. Environ. Prot.* **2019**, *123*, 344–350, doi:10.1016/j.psep.2019.01.028.
74. Spanò, A.; Laganà, P.; Visalli, G.; Maugeri, T.L.; Gugliandolo, C. In Vitro Antibiofilm Activity of an Exopolysaccharide from the Marine Thermophilic Bacillus Licheniformis T14. *Curr. Microbiol.* **2016**, *72*, 518–528, doi:10.1007/s00284-015-0981-9.
75. Dertli, E.; Mayer, M.J.; Narbad, A. Impact of the Exopolysaccharide Layer on Biofilms, Adhesion and Resistance to Stress in Lactobacillus Johnsonii FI9785. *BMC Microbiol.* **2015**, *15*, 8, doi:10.1186/s12866-015-0347-2.
76. Abdalla, A.K.; Ayyash, M.M.; Olaimat, A.N.; Osaili, T.M.; Al-Nabulsi, A.A.; Shah, N.P.; Holley, R. Exopolysaccharides as Antimicrobial Agents: Mechanism and Spectrum of Activity. *Front. Microbiol.* **2021**, *12*, 664395, doi:10.3389/fmicb.2021.664395.
77. Riaz Rajoka, M.S.; Wu, Y.; Mehwish, H.M.; Bansal, M.; Zhao, L. Lactobacillus Exopolysaccharides: New Perspectives on Engineering Strategies, Physiochemical Functions, and Immunomodulatory Effects on Host Health. *Trends Food Sci. Technol.* **2020**, *103*, doi:10.1016/j.tifs.2020.06.003.

Red Sea's Shore

Isolation and Screening

Bacterial Identification

EPS extraction and characterization

Biomedical Activities



Antioxidant

Anticoagulant

Anti-obesity

Anti-diabetic

Anti-inflammatory

Wound Healing

Anti- *H.pylori*

Antibacterial

## Supplementary Data

# Investigating the Multi-Targeted Pharmaceutical profile of an Exopolysaccharide from *Bacillus rugosus* SYG20 via In Vitro Evaluation of its Antioxidant, Anti-inflammatory, Anti-diabetic, Wound Healing and Antimicrobial Properties

**Table S1.** Culture and Morphological Characteristics of *Bacillus rugosus strain SYG20*

| **Culture and Morphological Features** | ***Bacillus rugosus* SYG20** |
|---|---|
| **Gram stain** | Gram +ve<br>(short rod) |
| **Colony surface** | Dull |
| **Colony texture** | Rough |
| **Color** | White |
| **Elevation** | Flat |
| **Edge** | Entire |
| **Whole colony** | Irregular<br>Large colony |
| **Pigmentation** | No |
| **Opacity of the bacterial colony** | Opaque |

**Table S2.** Physiological and biochemical Characteristics *Bacillus rugosus* strain SYG20

| **Physiological and Biochemical Features** | ***Bacillus rugosus* SYG20** |
|---|---|
| **Starch hydrolysis** | + |
| **Catalase test** | + |
| **Voges- Proskauer test** | + |
| **Simmon citrate test** | + |
| **Nitrate reduction** | + |
| **Carbohydrate fermentation** | |
| **Glucose** | + |
| **Maltose** | - |
| **Sucrose** | + |
| **Lactose** | - |




**Figure S1.**U.V Spectrum of EPSF9 isolated from *Bacillus rugosus* SYG2

**Total Antioxidant Capacity (TAC)**




| TAC Ascorbic con. µg/ml | Absorbance |
|---|---|
| 1000 | 1.295 |
| 800 | 0.963 |
| 600 | 0.692 |
| 400 | 0.455 |
| 200 | 0.211 |
| 100 | 0.124 |

**Figure S2.** TAC activity of Ascorbic acid

**Ferric reducing antioxidant power (FRAP) assay**




| FRAP ascorbic con. µg/ml | Absorbance |
|---|---|
| 1000 | 1.566 |
| 800 | 1.236 |
| 600 | 0.997 |
| 400 | 0.756 |
| 200 | 0.433 |
| 100 | 0.317 |

**Figure S3.** FRAP activity of Ascorbic acid

**Table S3.** EPSR9 Antibiofilm % against *St.aureus*, *E.faecalis*, and *K. pneumonia* at different MBC%

| **EPSR9/*St. aureus*** | **Replicate1 Ab** | **Replicate2 Ab** | **Replicate 3 Ab** | **Mean±SD** | **Anti-Biofilm Activity %** |
|---|---|---|---|---|---|
| Blank (Media only) | 0.005 | 0.001 | 0.003 | 0.003±0.002 | |
| Media+Organism (Cont.) | 1.963 | 1.955 | 1.96 | 1.959±0.004 | - |
| 25% of MBC | 1.455 | 1.463 | 1.463 | 1.460±0.005 | 37.06 |
| 50% of MBC | 0.925 | 0.911 | 0.904 | 0.913±0.011 | 60.70 |
| 75% of MBC | 0.639 | 0.647 | 0.643 | 0.643±0.004 | 67.28 |

| **EPSR9/ *E. faecalis*** | **Replicate1 Ab** | **Replicate2 Ab** | **Replicate 3 Ab** | **Mean± SD** | **Anti-Biofilm Activity %** |
|---|---|---|---|---|---|
| Blank (Media only) | 0.005 | 0.001 | 0.003 | 0.003±0.002 | |
| Media+Organism (Cont.) | 2.369 | 2.374 | 2.372 | 2.372±0.003 | - |
| 25% of MBC | 0.917 | 0.899 | 0.911 | 0.909±0.009 | 61.76 |
| 50% of MBC | 0.487 | 0.479 | 0.483 | 0.483±0.004 | 79.74 |
| 75% of MBC | 0.362 | 0.367 | 0.358 | 0.362±0.005 | 84.83 |



| **EPSR9/*K. pneumoniae*** | **Replicate1 Ab** | **Replicate2 Ab** | **Replicate 3 Ab** | **Mean± SD** | **Anti-Biofilm Activity %** |
|---|---|---|---|---|---|
| Blank (Media only) | 0.005 | 0.001 | 0.003 | 0.003±0.002 | |
| Media+Organism (Cont.) | 2.145 | 2.144 | 2.141 | 2.143±0.002 | - |
| 25% of MBC | 1.063 | 1.049 | 1.052 | 1.055±0.007 | 50.86 |
| 50% of MBC | 0.622 | 0.623 | 0.625 | 0.623±0.002 | 71.01 |
| 75% of MBC | 0.411 | 0.413 | 0.415 | 0.413±0.002 | 80.84 |